MacroGenics stock faces October data after a Q2 revenue miss
Published on 10/05/2026 at 10:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
MacroGenics stock (ISIN US5560991094) closed at USD 3.58 on Nasdaq on October 2, 2026, down 0.56 percent from the prior session. The company enters October with second-quarter revenue below expectations and a clinical data event scheduled for its MGC026 program.
Q2 revenue missed by USD 26.31 million
According to MarketBeat, MacroGenics reported USD 32.83 million in second-quarter 2026 revenue after analysts expected USD 59.14 million. The shortfall was USD 26.31 million, while reported quarterly EPS of USD 0.31 beat the consensus loss of USD 0.08 by USD 0.39.
The revenue result gives the stock a mixed operating picture: the per-share result exceeded expectations, but revenue conversion remains the central financial test for a clinical-stage biotechnology company. MacroGenics' investor page lists the second-quarter report dated August 13, 2026, alongside the company's August 2026 corporate presentation.
October data adds a pipeline checkpoint
MacroGenics is preparing investors for clinical information rather than another financial release. A report by Simply Wall St says the company plans to present dose-escalation and preliminary tumor-specific results for MGC026 at the ESMO 2026 Congress beginning October 23, 2026.
The same update identified MGC026 as a B7-H3-directed antibody-drug conjugate and said 74 patients had been enrolled as of July 8, 2026. The program is evaluating a 7.5 mg/kg dose every three weeks across recurrent or metastatic head and neck cancer, endometrial cancer, melanoma and soft tissue sarcoma cohorts.
Consensus target sits above the latest close
MarketBeat lists a Hold consensus from six analysts, with two Buy ratings, three Hold ratings and one Sell rating. The average target is USD 6.33, with a high of USD 11.00 and a low of USD 2.00; the October 2 price of USD 3.58 lies 43.4 percent below the average target.
That valuation gap sits beside a clear counter-factor: the company is still reporting losses while funding a broad clinical pipeline. For investors, the October clinical readout and the next revenue update are the two concrete checkpoints that can test whether the pipeline is translating into financial progress.
MacroGenics stock stays below USD 4
MacroGenics stock closed at USD 3.58 on Nasdaq on October 2, 2026, with a market capitalization of USD 228.1 million and volume of 980,529 shares.
MacroGenics stock facts
- Company: MacroGenics, Inc.
- ISIN: US5560991094
- Ticker: MGNX
- Trading venue: NASDAQ
- Closing price (October 2, 2026): USD 3.58
- Market capitalization: USD 228.1 million (as of October 2, 2026)
- 52-week range: USD 1.29-5.08 (as of October 2, 2026)
- Sector / Industry: Healthcare / Biotechnology
Upcoming dates for MacroGenics stock
- October 23, 2026: ESMO 2026 Congress clinical update for MGC026
